T
TrialNavigatorAI

Confidential Preview

This is a private prototype. Please enter the access password to continue.

Interactive Prototype Demo

See how TrialNavigatorAI navigates cancer care

Three synthetic patient profiles demonstrating how the prototype supports clinical trial discovery, plain-language guidance, and prepared conversations with the oncology team.

Demonstration only — synthetic data. TrialNavigatorAI does not diagnose, recommend treatment, determine trial eligibility, or replace medical advice. All trial options must be reviewed by the patient's oncology team. The patients shown below are fictional and were created for prototype demonstration purposes only. No real patient information is collected, stored, or processed.
Demo Patients

Three patient journeys, three trial pathways

Select a patient profile to see how TrialNavigatorAI surfaces relevant trial pathways, explains why they may be a fit, and prepares meaningful questions for the oncology team.

M
Maria R.
58 years old · Non-Small Cell Lung Cancer
Synthetic Profile

Patient Summary

Maria is a 58-year-old former teacher recently diagnosed with stage IIIB non-small cell lung adenocarcinoma. Genomic testing identified an EGFR exon 19 deletion. She has completed first-line treatment and her oncology team is exploring next-step options, including clinical trial pathways. She lives outside Boston and is willing to travel within New England.

Diagnosis
NSCLC, adenocarcinoma
Stage
IIIB
Biomarker
EGFR exon 19 deletion · PD-L1 25%
Prior Treatment
Osimertinib + chemoradiation
Location
Greater Boston, MA
Travel Range
Up to 200 miles
Search Criteria

How TrialNavigatorAI framed the search

ConditionNSCLC, Stage IIIB
BiomarkerEGFR exon 19 del
Prior Lines1 (osimertinib)
StatusRecruiting
DistanceWithin 200 mi of Boston
PhasePhase 1b–3
Sample Trial Pathways

Three trials that may be relevant

NCT-DEMO-04829 (synthetic) Phase 2

Osimertinib + MET Inhibitor in EGFR-Mutated NSCLC with Progression

Dana-Farber Cancer Institute · 14 mi Recruiting
Why this may be relevant: Maria has an EGFR exon 19 deletion and has already received osimertinib. This trial is specifically designed for patients with EGFR-positive NSCLC who progressed on first-line osimertinib, evaluating combination therapy with a MET inhibitor — a known resistance pathway. Her recent progression and biomarker profile match the inclusion framework. Her oncologist would confirm eligibility based on imaging, organ function, and prior treatment timing.
NCT-DEMO-05117 (synthetic) Phase 3

Next-Generation EGFR TKI versus Standard of Care in Advanced NSCLC

Massachusetts General Hospital · 8 mi Recruiting
Why this may be relevant: This Phase 3 study evaluates a fourth-generation EGFR-targeted therapy designed to overcome common resistance mutations seen after osimertinib. Maria's exon 19 deletion is among the genotypes the trial targets. The site is close to home, lowering travel burden during treatment.
NCT-DEMO-03945 (synthetic) Phase 1b

Bispecific Antibody Therapy for EGFR/MET-Driven Lung Cancers

Yale Cancer Center · 145 mi Recruiting
Why this may be relevant: An emerging therapy targeting both EGFR and MET pathways simultaneously. Patients with prior osimertinib exposure are eligible. Within Maria's stated travel range, though further than the Boston-based options.
Questions to ask the oncology team

Prepared questions for Maria's next visit

1.Given my EGFR exon 19 deletion and recent osimertinib treatment, which of these trial pathways might fit my situation best?
2.Should we test for resistance mutations like T790M or C797S before deciding on a next step?
3.What would the timeline look like if I were to enroll in a trial versus continuing standard-of-care therapy?
4.Are there benefits or risks to combination therapy versus a single-agent next-line treatment?
5.How would participation in a trial affect my ability to receive other treatments later?
J
James T.
64 years old · Metastatic Colorectal Cancer
Synthetic Profile

Patient Summary

James is a 64-year-old retired engineer with metastatic colorectal cancer (stage IV) with liver involvement. Tumor profiling revealed KRAS G12C mutation and microsatellite stable (MSS) status. He completed FOLFOX with bevacizumab and is now considering second-line options. He lives in Austin, Texas.

Diagnosis
Colorectal adenocarcinoma
Stage
IV (liver metastases)
Biomarker
KRAS G12C · MSS · BRAF wild-type
Prior Treatment
FOLFOX + bevacizumab
Location
Austin, TX
Travel Range
Texas-wide
Search Criteria

How TrialNavigatorAI framed the search

ConditionMetastatic CRC
BiomarkerKRAS G12C, MSS
Prior Lines1 (FOLFOX/bev)
StatusRecruiting
LocationTexas-wide
PhasePhase 1b–3
Sample Trial Pathways

Three trials that may be relevant

NCT-DEMO-06234 (synthetic) Phase 2

KRAS G12C Inhibitor + Anti-EGFR Combination in Advanced Colorectal Cancer

MD Anderson Cancer Center · 165 mi Recruiting
Why this may be relevant: James carries a KRAS G12C mutation, one of the few KRAS mutations now therapeutically targetable. This trial pairs a KRAS G12C inhibitor with anti-EGFR therapy — a combination shown to overcome resistance seen with single-agent KRAS inhibitors in colorectal cancer. The trial accepts patients with one prior line of therapy.
NCT-DEMO-05892 (synthetic) Phase 3

Novel KRAS G12C Inhibitor versus Standard Second-Line Therapy

Texas Oncology, Austin · 4 mi Recruiting
Why this may be relevant: A randomized Phase 3 study comparing a next-generation KRAS G12C inhibitor head-to-head with standard second-line chemotherapy. James's biomarker profile matches the inclusion criteria, and the site is in his home city — minimizing travel and disruption.
NCT-DEMO-04671 (synthetic) Phase 1b

Triple Combination: KRAS Inhibitor + MEK Inhibitor + Immunotherapy in MSS CRC

UT Southwestern, Dallas · 195 mi Recruiting
Why this may be relevant: MSS colorectal cancers historically respond poorly to immunotherapy alone. This trial explores whether combining targeted therapy with checkpoint inhibition can sensitize MSS tumors. James's KRAS G12C and MSS status fit the trial's specific patient population.
Questions to ask the oncology team

Prepared questions for James's next visit

1.What does my KRAS G12C mutation mean for my treatment choices going forward?
2.Given my MSS status, would immunotherapy combinations be worth considering?
3.What are the differences between Phase 2, Phase 3, and Phase 1b trials in terms of risk and benefit?
4.Would trial participation delay or affect my access to standard second-line therapies?
5.How do you decide between a local trial and one that may require traveling out of state?
E
Elena S.
47 years old · HER2-Positive Breast Cancer
Synthetic Profile

Patient Summary

Elena is a 47-year-old graphic designer diagnosed with stage III HER2-positive, hormone receptor-positive invasive ductal carcinoma. She completed neoadjuvant chemotherapy with trastuzumab and pertuzumab, followed by surgery, but had residual disease on pathology. She lives in San Diego and is exploring options to reduce recurrence risk.

Diagnosis
Invasive ductal carcinoma
Stage
III · residual disease post-NAC
Biomarker
HER2+ · ER+/PR+ · BRCA wild-type
Prior Treatment
TCHP + surgery
Location
San Diego, CA
Travel Range
Southern California
Search Criteria

How TrialNavigatorAI framed the search

ConditionHER2+ Breast Cancer
BiomarkerHER2+, ER/PR+
SettingPost-NAC residual
StatusRecruiting
LocationSoCal
PhasePhase 2–3
Sample Trial Pathways

Three trials that may be relevant

NCT-DEMO-07712 (synthetic) Phase 3

Trastuzumab Deruxtecan versus T-DM1 in HER2+ Breast Cancer with Residual Disease

UC San Diego Moores Cancer Center · 8 mi Recruiting
Why this may be relevant: Elena had residual disease after neoadjuvant therapy — a setting where trastuzumab deruxtecan (T-DXd) has shown promise compared to T-DM1, the current standard. The trial population specifically targets HER2-positive patients in her exact clinical setting. The site is local.
NCT-DEMO-06458 (synthetic) Phase 2

CDK4/6 Inhibitor + Endocrine Therapy Added to HER2-Targeted Treatment

City of Hope, Duarte · 110 mi Recruiting
Why this may be relevant: Elena's tumor is both HER2+ and hormone receptor-positive — a "triple-positive" profile where adding hormonal therapy and CDK4/6 inhibition to HER2-targeted treatment is being actively studied for improved long-term outcomes.
NCT-DEMO-05033 (synthetic) Phase 2

Tucatinib Combination Therapy for High-Risk HER2+ Early Breast Cancer

Cedars-Sinai, Los Angeles · 120 mi Recruiting
Why this may be relevant: A trial exploring whether adding tucatinib — a HER2-targeted therapy known to cross the blood-brain barrier — to standard adjuvant therapy reduces recurrence and brain metastasis risk in patients with residual disease. Within Elena's stated travel range.
Questions to ask the oncology team

Prepared questions for Elena's next visit

1.What does residual disease after neoadjuvant therapy mean for my long-term outlook?
2.Should we consider trastuzumab deruxtecan over T-DM1 in my case, and what's the evidence?
3.Given that I'm both HER2+ and hormone receptor-positive, how should treatment sequencing work?
4.What's my risk of brain metastasis, and do any trials address that specifically?
5.How would joining a trial affect my fertility, work, and quality of life decisions?
A reminder: Every trial pathway, biomarker explanation, and question shown above is illustrative only. TrialNavigatorAI is designed to support, not replace, clinical judgment — surfacing possibilities, framing conversations, and helping patients walk into their oncology visit better prepared. All real decisions belong to the care team and the patient.